이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Cardiff Oncology 관리
관리 기준 확인 3/4
Cardiff Oncology's CEO는 Mark Erlander, May2020 에 임명되었습니다 의 임기는 4.08 년입니다. 총 연간 보상은 $ 1.55M, 38.4% 로 구성됩니다. 38.4% 급여 및 61.6% 보너스(회사 주식 및 옵션 포함). 는 $ 61.21K 가치에 해당하는 회사 주식의 0.055% 직접 소유합니다. 61.21K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 9.8 년입니다.
주요 정보
Mark Erlander
최고 경영자
US$1.5m
총 보상
CEO 급여 비율 | 38.4% |
CEO 임기 | 4.1yrs |
CEO 소유권 | 0.05% |
경영진 평균 재임 기간 | 2.4yrs |
이사회 평균 재임 기간 | 9.8yrs |
최근 관리 업데이트
Recent updates
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24CEO 보상 분석
날짜 |
---|